Table 2. Univariate analysis of the association between patients’ characteristics and T790M status of blood plasma detection.
| Characteristics | No. | T790M mutation states, n (%) | P value | |
|---|---|---|---|---|
| + | − | |||
| Age (years) | ||||
| ≤60 | 64 | 25 (39.1) | 39 (60.9) | 0.438 |
| >60 | 125 | 44 (35.2) | 81 (64.8) | |
| Sex | ||||
| Male | 64 | 27 (42.19) | 37 (57.81) | 0.246 |
| Female | 125 | 42 (33.6) | 83 (66.4) | |
| Baseline EGFR mutation status | ||||
| 19 del | 99 | 45 (45.45) | 54 (54.55) | 0.026 |
| 21-L858R | 84 | 22 (26.19) | 62 (73.81) | |
| Others | 6 | 2 (33.33) | 4 (66.67) | |
| First generation TKI | ||||
| Icotinib | 96 | 28 (29.17) | 68 (70.83) | 0.074 |
| Gefitinib | 90 | 39 (43.33) | 51 (56.67) | |
| Erlotinib | 3 | 2 (66.67) | 1 (33.33) | |
| Disease progression modes | ||||
| Gradual progression | 78 | 21 (26.92) | 57 (73.08) | 0.031 |
| Local progression | 48 | 24 (50.00) | 24 (50.00) | |
| Dramatic progression | 63 | 24 (38.10) | 39 (61.90) | |
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.